Throughout 2022, Eli Lilly emerged as a standout performer in the healthcare sector, largely due to excitement surrounding its blockbuster potential in diabetes and obesity treatments. Specifically, the launch and clinical success of positioned the company as a leader in a rapidly expanding market.
The maintenance of the Neutral stance did little to dampen investor enthusiasm in the long term. While the rating suggested a lack of immediate "buy" urgency from the bank's perspective, Eli Lilly finished 2022 as one of the best-performing large-cap pharmaceutical companies, setting the stage for its continued ascent in the years that followed.
However, despite these strong fundamentals, Goldman Sachs analysts opted for a outlook. The primary rationale centered on "valuation discipline." At various points in 2022, Eli Lilly’s stock traded at a significant premium compared to its peers in the S&P 500 Healthcare Sector , leading analysts to suggest that much of the near-term growth was already priced into the shares. Pipeline Successes and Challenges Throughout 2022, Eli Lilly emerged as a standout
A opinion from Goldman Sachs typically indicates that the firm expects the stock’s performance to be generally in line with the average return of the stocks in the analyst's coverage universe. For Eli Lilly, this rating reflected a balance between:
As a "defensive" stock, Eli Lilly benefited from investor rotation away from high-growth tech and into stable healthcare companies during the inflationary periods of 2022. Why "Neutral"? While the rating suggested a lack of immediate
AI responses may include mistakes. For financial advice, consult a professional. Learn more
The FDA approval of tirzepatide for type 2 diabetes in May 2022 served as a major catalyst for the stock. Pipeline Successes and Challenges A opinion from Goldman
Eli Lilly's 2022 performance was characterized by several key milestones: